Tumor-Associated and Systemic Autoimmunity in Pre-Clinical Breast Cancer among Post-Menopausal Women
Autoantibodies to tumor-associated antigens (anti-TAA) are potential biomarkers for breast cancer, but their relationship systemic autoimmunity as ascertained though antinuclear antibodies (ANA) is unknown and warrants consideration given the common occurrence of autoimmunity and autoimmune diseases...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/13/11/1566 |
| _version_ | 1797459997310844928 |
|---|---|
| author | Christine G. Parks Lauren E. Wilson Michela Capello Kevin D. Deane Samir M. Hanash |
| author_facet | Christine G. Parks Lauren E. Wilson Michela Capello Kevin D. Deane Samir M. Hanash |
| author_sort | Christine G. Parks |
| collection | DOAJ |
| description | Autoantibodies to tumor-associated antigens (anti-TAA) are potential biomarkers for breast cancer, but their relationship systemic autoimmunity as ascertained though antinuclear antibodies (ANA) is unknown and warrants consideration given the common occurrence of autoimmunity and autoimmune diseases among women. The relationship between anti-TAAs and ANA among women who were later diagnosed with breast cancer and others who remained cancer free in the Women’s Health Initiative cohort. The study sample included 145 post-menopausal women with baseline ANA data. A total of 37 ANA-positive women who developed breast cancer (i.e., cases; mean time to diagnosis 6.8 years [SE 3.9]) were matched to a random sample of 36 ANA-negative cases by age and time to diagnosis. An age-matched control sample was selected including 35 ANA-positive and 37 ANA-negative women who did not develop breast cancer (i.e., controls; follow-up time ~13 years [SE 3]). Baseline sera were assessed for Immunoglobulin G (IgG) antibodies, measured by custom microarray for 171 breast and other cancer-associated TAA. We used linear regression to estimate cross-sectional associations of ANA with log-transformed anti-TAA among cases and controls. Most anti-TAA did not vary by ANA status. Two anti-TAA were elevated in ANA-positive compared to ANA-negative cases: anti-PGM3 (<i>p</i> = 0.004) and anti-TTN (<i>p</i> = 0.005, especially in cases up to 7 years before diagnosis, <i>p</i> = 0.002). Anti-TAA antibodies were not generally related to ANA, a common marker of systemic autoimmunity. Associations of ANA with particular antigens inducing autoimmunity prior to breast cancer warrant further investigation. |
| first_indexed | 2024-03-09T16:59:42Z |
| format | Article |
| id | doaj.art-bc8a8df2ac0b44b9bfeeb6ca4009ae39 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-09T16:59:42Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-bc8a8df2ac0b44b9bfeeb6ca4009ae392023-11-24T14:31:45ZengMDPI AGBiomolecules2218-273X2023-10-011311156610.3390/biom13111566Tumor-Associated and Systemic Autoimmunity in Pre-Clinical Breast Cancer among Post-Menopausal WomenChristine G. Parks0Lauren E. Wilson1Michela Capello2Kevin D. Deane3Samir M. Hanash4Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USACenter for Population Health, Duke University School of Medicine, Durham, NC 27710, USADepartments of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADivision of Rheumatology, University of Colorado School of Medicine, Aurora, CO 80045, USADepartments of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAAutoantibodies to tumor-associated antigens (anti-TAA) are potential biomarkers for breast cancer, but their relationship systemic autoimmunity as ascertained though antinuclear antibodies (ANA) is unknown and warrants consideration given the common occurrence of autoimmunity and autoimmune diseases among women. The relationship between anti-TAAs and ANA among women who were later diagnosed with breast cancer and others who remained cancer free in the Women’s Health Initiative cohort. The study sample included 145 post-menopausal women with baseline ANA data. A total of 37 ANA-positive women who developed breast cancer (i.e., cases; mean time to diagnosis 6.8 years [SE 3.9]) were matched to a random sample of 36 ANA-negative cases by age and time to diagnosis. An age-matched control sample was selected including 35 ANA-positive and 37 ANA-negative women who did not develop breast cancer (i.e., controls; follow-up time ~13 years [SE 3]). Baseline sera were assessed for Immunoglobulin G (IgG) antibodies, measured by custom microarray for 171 breast and other cancer-associated TAA. We used linear regression to estimate cross-sectional associations of ANA with log-transformed anti-TAA among cases and controls. Most anti-TAA did not vary by ANA status. Two anti-TAA were elevated in ANA-positive compared to ANA-negative cases: anti-PGM3 (<i>p</i> = 0.004) and anti-TTN (<i>p</i> = 0.005, especially in cases up to 7 years before diagnosis, <i>p</i> = 0.002). Anti-TAA antibodies were not generally related to ANA, a common marker of systemic autoimmunity. Associations of ANA with particular antigens inducing autoimmunity prior to breast cancer warrant further investigation.https://www.mdpi.com/2218-273X/13/11/1566autoantibodiesbreast cancerepidemiologyimmunologybiomarkers |
| spellingShingle | Christine G. Parks Lauren E. Wilson Michela Capello Kevin D. Deane Samir M. Hanash Tumor-Associated and Systemic Autoimmunity in Pre-Clinical Breast Cancer among Post-Menopausal Women Biomolecules autoantibodies breast cancer epidemiology immunology biomarkers |
| title | Tumor-Associated and Systemic Autoimmunity in Pre-Clinical Breast Cancer among Post-Menopausal Women |
| title_full | Tumor-Associated and Systemic Autoimmunity in Pre-Clinical Breast Cancer among Post-Menopausal Women |
| title_fullStr | Tumor-Associated and Systemic Autoimmunity in Pre-Clinical Breast Cancer among Post-Menopausal Women |
| title_full_unstemmed | Tumor-Associated and Systemic Autoimmunity in Pre-Clinical Breast Cancer among Post-Menopausal Women |
| title_short | Tumor-Associated and Systemic Autoimmunity in Pre-Clinical Breast Cancer among Post-Menopausal Women |
| title_sort | tumor associated and systemic autoimmunity in pre clinical breast cancer among post menopausal women |
| topic | autoantibodies breast cancer epidemiology immunology biomarkers |
| url | https://www.mdpi.com/2218-273X/13/11/1566 |
| work_keys_str_mv | AT christinegparks tumorassociatedandsystemicautoimmunityinpreclinicalbreastcanceramongpostmenopausalwomen AT laurenewilson tumorassociatedandsystemicautoimmunityinpreclinicalbreastcanceramongpostmenopausalwomen AT michelacapello tumorassociatedandsystemicautoimmunityinpreclinicalbreastcanceramongpostmenopausalwomen AT kevinddeane tumorassociatedandsystemicautoimmunityinpreclinicalbreastcanceramongpostmenopausalwomen AT samirmhanash tumorassociatedandsystemicautoimmunityinpreclinicalbreastcanceramongpostmenopausalwomen |